ABT-737, a small molecule Bcl-2/Bcl-xL antagonist, increases antimitotic-mediated apoptosis in human prostate cancer cells

ABT-737, a small molecule Bcl-2/Bcl-xL antagonist, increases antimitotic-mediated apoptosis in human prostate cancer cells

Castration-resistant prostate cancer (CRPC) expresses high levels of the anti-apoptotic proteins Bcl-2, Bcl-xL and Mcl-1, resulting in resistance to apoptosis and association with poor prognosis. Docetaxel, an antimitotic drug that is the first-line treatment strategy for CRPC, is known to provide a...

Full description

Bibliographic Details
Main Authors: Ricardo Parrondo, Alicia de las Pozas, Teresita Reiner, Carlos Perez-Stable
Format: Article
Language:English
Published: PeerJ Inc. 2013-09-01
Series:PeerJ
Subjects:
Apoptosis
Antimitotic
ABT-737
Bcl-2 family
Cyclin B1/Cdk1
Online Access:https://peerj.com/articles/144.pdf

Internet

https://peerj.com/articles/144.pdf

Similar Items